Eribulin Mesylate

Product Information

  • Proprietary Name: Nibulin®
  • Generic Name: Eribulin Mesylate
  • Dosage Form: Vial
  • Strengths: 1 mg/2 ml
  • Indications: Locally Advanced or Metastatic Breast Cancer and Liposarcoma



Eribulin Mesylate is indicated for the treatment of patients with locally advanced or metastatic breast cancer and liposarcoma.

Apply for a Job Position

Curious about job opportunities?

© NanoAlvand. All rights reserved. Powered by ِDGN.